Merck KGaA – Product Pipeline Review

Global Markets Direct’s, ‘Merck KGaA – Product Pipeline Review – 2016’, provides an overview of the Merck KGaA’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Merck KGaA, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Merck KGaA

The report provides overview of Merck KGaA including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Merck KGaA’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Merck KGaA’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Merck KGaA’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Merck KGaA

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Merck KGaA’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 7

Merck KGaA Snapshot 8

Merck KGaA Overview 8

Key Information 8

Key Facts 8

Merck KGaA - Research and Development Overview 9

Key Therapeutic Areas 9

Merck KGaA - Pipeline Review 14

Pipeline Products by Stage of Development 14

Pipeline Products - Monotherapy 15

Pipeline Products - Combination Treatment Modalities 16

Pipeline Products - Partnered Products 17

Partnered Products/Combination Treatment Modalities 18

Pipeline Products - Out-Licensed Products 20

Out-Licensed Products/Combination Treatment Modalities 21

Merck KGaA - Pipeline Products Glance 22

Merck KGaA - Late Stage Pipeline Products 22

Filing rejected/Withdrawn Products/Combination Treatment Modalities 22

Phase III Products/Combination Treatment Modalities 23

Merck KGaA - Clinical Stage Pipeline Products 24

Phase II Products/Combination Treatment Modalities 24

Phase I Products/Combination Treatment Modalities 25

Merck KGaA - Early Stage Pipeline Products 26

Preclinical Products/Combination Treatment Modalities 26

Discovery Products/Combination Treatment Modalities 27

Merck KGaA - Drug Profiles 28

cetuximab 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

avelumab 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

choriogonadotropin alfa 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

cladribine 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

atacicept 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

M-2736 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

pimasertib hydrochloride 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

sprifermin 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

tecemotide 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

tepotinib 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

BGB-283 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

BGB-290 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

DI-B4 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

L-Praziquantel 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

M-1095 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

M-2698 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

M-2951 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

M-3814 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

M-7824 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

M-9241 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

MSC-2015103B 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

pimasertib hydrochloride + voxtalisib 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

rimeporide 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

ALX-0751 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

AS-605240 69

Product Description 69

Mechanism of Action 69

R&D Progress 69

cilengitide 71

Product Description 71

Mechanism of Action 71

R&D Progress 71

DDD-498 74

Product Description 74

Mechanism of Action 74

R&D Progress 74

M-7583 75

Product Description 75

Mechanism of Action 75

R&D Progress 75

Monoclonal Antibody Conjugates for Oncology 76

Product Description 76

Mechanism of Action 76

R&D Progress 76

Small Molecule to Inhibit Aurora B Kinase for Cancer 77

Product Description 77

Mechanism of Action 77

R&D Progress 77

Small Molecules to Inhibit CDK8 for Colorectal Carcinoma 78

Product Description 78

Mechanism of Action 78

R&D Progress 78

Vaccine 1 for Cancer 79

Product Description 79

Mechanism of Action 79

R&D Progress 79

Vaccine 2 for Cancer 80

Product Description 80

Mechanism of Action 80

R&D Progress 80

Small Molecule to Inhibit SYK for Inflammation 81

Product Description 81

Mechanism of Action 81

R&D Progress 81

Small Molecule to Inhibit WNT Pathway for Oncology 82

Product Description 82

Mechanism of Action 82

R&D Progress 82

Small Molecules for Autoimmune Disorder and Oncology 83

Product Description 83

Mechanism of Action 83

R&D Progress 83

Small Molecules for Multiple Sclerosis 84

Product Description 84

Mechanism of Action 84

R&D Progress 84

Small Molecules to Agonize TNFR for Cancer 85

Product Description 85

Mechanism of Action 85

R&D Progress 85

Merck KGaA - Pipeline Analysis 86

Merck KGaA - Pipeline Products by Target 86

Merck KGaA - Pipeline Products by Route of Administration 89

Merck KGaA - Pipeline Products by Molecule Type 90

Merck KGaA - Pipeline Products by Mechanism of Action 91

Merck KGaA - Recent Pipeline Updates 93

Merck KGaA - Dormant Projects 103

Merck KGaA - Discontinued Pipeline Products 105

Discontinued Pipeline Product Profiles 105

abituzumab 105

anastrozole 105

atacicept 106

cilengitide 106

cladribine 106

Drug to Antagonize Oxytocin Receptor for Pre-term Labor 106

EMD-1204831 106

emfilermin 106

EML-4156 106

M-1095 106

matuzumab 106

MSB-0010445 107

onercept 107

Osteopontin 107

pimasertib hydrochloride 107

plovamer acetate 107

sarizotan hydrochloride 107

tecemotide 107

tucotuzumab celmoleukin 108

Merck KGaA - Company Statement 109

Merck KGaA - Locations And Subsidiaries 112

Head Office 112

Other Locations & Subsidiaries 112

Appendix 122

Methodology 122

Coverage 122

Secondary Research 122

Primary Research 122

Expert Panel Validation 122

Contact Us 122

Disclaimer 123

List of Tables

List of Tables

Merck KGaA, Key Information 8

Merck KGaA, Key Facts 8

Merck KGaA – Pipeline by Indication, 2016 11

Merck KGaA – Pipeline by Stage of Development, 2016 14

Merck KGaA – Monotherapy Products in Pipeline, 2016 15

Merck KGaA – Combination Treatment Modalities in Pipeline, 2016 16

Merck KGaA – Partnered Products in Pipeline, 2016 17

Merck KGaA – Partnered Products/ Combination Treatment Modalities, 2016 18

Merck KGaA – Out-Licensed Products in Pipeline, 2016 20

Merck KGaA – Out-Licensed Products/ Combination Treatment Modalities, 2016 21

Merck KGaA – Filing rejected/Withdrawn, 2016 22

Merck KGaA – Phase III, 2016 23

Merck KGaA – Phase II, 2016 24

Merck KGaA – Phase I, 2016 25

Merck KGaA – Preclinical, 2016 26

Merck KGaA – Discovery, 2016 27

Merck KGaA – Pipeline by Target, 2016 86

Merck KGaA – Pipeline by Route of Administration, 2016 89

Merck KGaA – Pipeline by Molecule Type, 2016 90

Merck KGaA – Pipeline Products by Mechanism of Action, 2016 91

Merck KGaA – Recent Pipeline Updates, 2016 93

Merck KGaA – Dormant Developmental Projects,2016 103

Merck KGaA – Discontinued Pipeline Products, 2016 105

Merck KGaA, Subsidiaries 112

List of Figures

List of Figures

Merck KGaA – Pipeline by Top 10 Indication, 2016 10

Merck KGaA – Pipeline by Stage of Development, 2016 14

Merck KGaA – Monotherapy Products in Pipeline, 2016 15

Merck KGaA – Partnered Products in Pipeline, 2016 17

Merck KGaA – Out-Licensed Products in Pipeline, 2016 20

Merck KGaA – Pipeline by Top 10 Target, 2016 86

Merck KGaA – Pipeline by Route of Administration, 2016 89

Merck KGaA – Pipeline by Molecule Type, 2016 90

Merck KGaA – Pipeline Products by Top 10 Mechanism of Action, 2016 91

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports